Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05617872Completed
Randomised trial of acetic acid in pancreatic cancer (PC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: KRAS mutation at 6 months. Started Dec 2022; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05617872.